1934results about "Urinary tract/kidney cells" patented technology

The present invention provides a method for packaging a BaEV retroviral vector. The method includes constructing a stable BaEV retroviral packaging cell line, transfecting a retroviral vector plasmid containing a target sequence into a virus-producing cell line, where the virus-producing cell line is a HEK293T cell line or its derivative cell line, to harvest the transiently transfected and virus-producing retroviral vector, mixing it with the stable BaEV retroviral packaging cell line, and promoting the transduction of the retroviral vector into the stable BaEV retroviral packaging cell line by horizontal centrifugation. The present invention can achieve the packaging of a BAEV-type retroviral vector carrying a CD19CAR foreign gene plasmid, construct a BAEV-type retroviral vector-producing cell line, and produce a high-titer BAEV-type retroviral vector.

The invention discloses an anti-interleukin-6 antibody or a reagent and a kit for detecting interleukin-6, and relates to the field of antibodies. The anti-interleukin-6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin-6, and has good affinity or activity.

The invention provides a porcine epidemic diarrhea virus S protein mutant, a nucleic acid molecule, a subunit vaccine and application. Compared with wild type porcine epidemic diarrhea virus S protein, the porcine epidemic diarrhea virus S protein mutant has the advantage that amino acid at the 1076th site, amino acid at the 1077th site, amino acid at the 1016th site and amino acid at the 1017th site are mutated into proline. The natural trimer which is stable and maintains the conformation of the S protein before fusion is constructed, the safe and efficient PEDV subunit vaccine is obtained, and the use effect and immunogenicity of the porcine epidemic diarrhea vaccine can be improved; moreover, compared with a wild type S protein, the porcine epidemic diarrhea virus S protein mutant disclosed by the invention has a higher expression quantity.

The invention discloses an anti-cortisol antibody or a cortisol detection reagent and kit, and relates to the field of antibodies. The anti-cortisol antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cortisol, and has good affinity or activity.

The invention relates to a drug delivery carrier based on extracellular vesicles and application thereof.The drug delivery carrier contains extracellular vesicle scaffold protein and recombinant membrane fusion protein, the recombinant membrane fusion protein comprises a first fragment and a second fragment, the amino acid sequence of the first fragment is shown as SEQ ID NO: 5, and the amino acid sequence of the second fragment is shown as SEQ ID NO: 6; the second fragment has n amino acids, the sequence of the second fragment is the sequence of the first n amino acids at the N end of the amino acid sequence as shown in SEQ ID NO: 7, and n is an integer between 50 and 200. According to the drug delivery carrier disclosed by the invention, the efficiency of releasing drug active molecules before reaching lysosome is remarkably improved, and the drug effect of extracellular vesicle drugs can be improved.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein and application of the antibody, and relates to the technical field of biological medicine. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 and / or HPV18 type E2 protein. Based on the antibody provided by the invention, a reagent, a kit, a test strip, an antibody chip, an antibody probe or a detector for detecting the HPV16 and / or HPV18 type E2 antigen can be developed. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity / specificity, high precision, high accuracy, fast detection and strong tolerance, and can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigens.

The invention discloses a fusion protein and application thereof. Fusion expression is carried out on R ring binding domains from different species sources and a single gene base editor, and it is found that compared with a base editor before fusion, the base editing efficiency of the obtained fusion protein is improved, and a base editing window is widened. According to the method, the R-ring binding structure domain is fused with the single-gene base editor, so that the base editing efficiency can be improved, and an editing window can be adjusted, so that the method can be suitable for more base editing scenes. The method is beneficial to popularization and application of a single-gene editing technology, and has wide application prospects in prevention and / or treatment of diseases and construction of animal models or plant varieties.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

The invention relates to the field of cell biology, and particularly discloses an exosome as well as a preparation method and application thereof. The method for preparing the exosome comprises the following steps: (1) introducing nucleotide sequences for coding a signal peptide TPA and an epidermal growth factor into an AAVS1 region of a host cell, such as a sequence shown in SEQ ID No.9 and a sequence shown in SEQ ID No.10, so as to obtain a modified host cell; and (2) collecting the exosome secreted by the modified host cell. The expression level of EGF mRNA in the exosome can be remarkably improved, so that the obtained exosome has a better effect in skin wound treatment.

The invention relates to the technical field of disinfection effect evaluation, and discloses a method for evaluating the virus disinfection effect of virus aerosol. According to the method for evaluating the virus killing effect of the virus aerosol, a real virus is simulated by adopting a pseudovirus, so that the biological safety risk is avoided; through the innovative pseudovirus activity detection method, the experimental operation complexity is greatly reduced, the detection time is shortened, meanwhile, the detection sensitivity is improved, and the method can be applied to the disinfection effect test and evaluation of scientific research and commercial air disinfection equipment (such as ultraviolet disinfection equipment).

The invention provides a UTR (Untranslated Region) sequence for improving mRNA (Messenger Ribonucleic Acid) stability and translation efficiency and application of the UTR sequence, and particularly provides an mRNA molecule which comprises a coding region for coding polypeptide or protein and a fragment thereof, a 5 'UTR sequence positioned at the upstream of the coding region and / or a 3' UTR sequence positioned at the downstream of the coding region, the 5 'UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 1, and the 3' UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 2; and / or, the 5 'UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 3, and the 3' UTR sequence is a nucleotide sequence as shown in SEQ ID NO: 4. According to the present invention, the mRNA stability and the translation efficiency are improved through the new and optimized UTR sequence, and the UTR sequence can be used as the element for enhancing the RNA expression efficiency in the nucleic acid treatment drug or the mRNA vaccine so as to provide more and better choices for the mRNA therapy.

A recombinant humanized collagen type I alpha-1 (rhCol1A1), and an expression vector and use thereof are provided, belonging to the technical field of bioengineering. The rhCol1A1 has an amino acid sequence of SEQ ID NO: 1. This aim is to solve the problem of difficulty in expressing soluble full-length humanized collagen in Escherichia coli prokaryotic expression systems, and differences between the recombinant collagen and humanized collagen in yeast expression systems. It is proposed that the rhCol1A1 chain is expressed in Expi293F human embryonic kidney cells, and the protein expression level is increased using a fusion expression plasmid, enabling the expression of full-length humanized collagen type I alpha 1 chain. Activity studies have shown that the expressed rhCol1A1 exhibits a desirable activity in promoting cell migration, and may be widely used in the fields of biomedicine, tissue engineering, skin care, and food.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein, an antibody conjugate and application of the antibody conjugate, and relates to the technical field of medical biology. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1, and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity, high intermediate precision, high accuracy, consistent linear range of standard curves, fast detection and strong tolerance for the HPV16 and / or HPV18 type E2 antigen, can be used for quality control in the production process of the recombinant human HPV16 and / or HPV18 type E2 antigen, and has wide application prospects. The antigen content in the vaccine can be efficiently and accurately quantified, and the quality of the vaccine can be monitored.

The invention belongs to the technical field of immunodetection, and discloses a rabbit monoclonal antibody mAb6 of an anti-mouse immune globulin G2a subtype (IgG2a) and application thereof. The rabbit monoclonal antibody mAb6 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence KSVYKNNY, the LCDR2 comprises an amino acid sequence GTN, and the LCDR3 comprises an amino acid sequence AGGYID; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence RFSLSNYR, the HCDR2 comprises an amino acid sequence IFTRGST, and the HCDR3 comprises an amino acid sequence ARGWNS. The rabbit monoclonal antibody disclosed by the invention can be combined with a mouse immune globulin G2a subtype (IgG2a) in a high-specificity manner, can be applied to immunodetection, and provides a basis for further preparation of engineering antibodies.

The present invention discloses a nano antibody against BCMA and its preparation method and application, and relates to the field of biomedical technology. The present invention uses CRISPR / Cas9 technology to knock out B2M and TRAC genes in T cells to prepare universal CAR-T cells; the nano antibody targeting BCMA and the natural ligand SIRPα extracellular N-terminal V region of CD47, the transmembrane region of CD28, the intracellular signal region of 4-1BB and the intracellular signal region of CD3ζ are connected in series to form a dual-targeted chimeric antigen receptor for the treatment of multiple myeloma, so as to solve the high recurrence problem faced by CAR-T cell therapy in the treatment of multiple myeloma. The universal CAR-T cells prepared by the present invention have strong killing activity against multiple myeloma cells, effectively improve the treatment effect, and provide a key material for the subsequent development of adoptive immunotherapy with high efficiency and lasting anti-tumor activity.

The invention belongs to the technical field of biology, and provides an electroporation buffer solution applied to exosome electroporation, the pH value is 6.8-9.8, the osmotic pressure is 80-320 mosm, water is used as a solvent, and the electroporation buffer solution comprises the following components: 15-25% w / v of iodixanol, 1.035-1.265 mM of KH2PO4, 22.5-27.5 mM of KCl, 0.18-0.22 mM of EDTA-2Na and 18-22 mM of HEPES. The electroporation buffer solution provided by the invention can improve the loading efficiency of the load and reduce damage to an exosome membrane structure and internal bioactive molecules in an electroporation process. The electroporation buffer solution can effectively reduce aggregation and fusion phenomena of exosomes after electroporation, and improves the stability and integrity of the exosomes. The electroporation buffer solution provided by the invention can improve the application degree of the exosome as a targeting drug delivery system.

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention discloses an anti-cortisol antibody or a cortisol detection reagent and kit, and relates to the field of antibodies. The anti-cortisol antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cortisol, and has good affinity or activity.

The invention belongs to the technical field of biological medicines, and particularly relates to a sperm injury repair model and an establishment method thereof. Comprising the following steps: step 1, establishing a sperm lead poisoning model; and 2, establishing a lead poisoning sperm repair model. The method for establishing the lead poisoning sperm repair model in the step 2 comprises the following steps: (1) preparing a preparation for optimizing sperm functions in an extracellular vesicle way; (2) repairing the damaged sperms by using the preparation for optimizing the sperm function through the extracellular vesicles; and (3) detecting the activity of the repaired sperms. In the invention, by establishing a sperm injury repair model and adopting an extracellular vesicle modification technology, the key functional protein is introduced into the extracellular vesicle, and the method has important significance on auxiliary researches such as development and research of related drugs for improving sperm injury and improving sperm motility of asthenospermia patients in vitro.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb32 or an antigen binding fragment, the anti-T3 antibody mAb32 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is IAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb32 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, and when a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The invention discloses a bispecific nano antibody targeting CXCL1 and PD-L1 and application thereof, and belongs to the technical field of antibody engineering and bioengineering. The bispecific nano-antibody targeting CXCL1 and PD-L1 comprises at least one nano-antibody for recognizing a target CXCL1 and a nano-antibody for recognizing a target PD-L1, and nano-antibody monomers are connected through a linker. The bispecific nano-antibody targeting PD-L1 / CXCL1 provided by the invention has a unique structure, so that the bispecific nano-antibody targeting PD-L1 / CXCL1 has specific recognition and binding capacities to CXCL1 and PD-L1, the affinity to CXCL1 reaches 1.08 nM, the affinity to PD-L1 reaches 1.09 nM, drug resistance of a patient to antibody treatment caused by immune escape can be effectively prevented, and the bispecific nano-antibody targeting PD-L1 / CXCL1 is suitable for more patients and has good clinical application prospects. And a new thought is provided for CRC treatment.

The present disclosure belongs to the field of biotechnology, and specifically relates to a method for efficiently infecting human natural killer (NK) cells and other immune cells with a pseudovirus. Specifically, a viral transfection system provided in the present disclosure has an envelope plasmid with a protein having an X—Y—Z structure. The X is an extracellular (ex) structure of a gibbon ape leukemia virus (GALV) envelope glycoprotein, the Y is a transmembrane (TM) structure of the GALV envelope glycoprotein, and the Z is an intracellular segment portion of a murine virus gene.

The invention discloses a temperature-controllable preparation method for tissue temperature dissociation into single cells and application, the temperature-controllable preparation method for tissue temperature dissociation into single cells comprises the following steps: S1, providing a tissue sample, and pre-treating the tissue sample to obtain a sample block; s2, mixing the sample blocks with a compound digestive enzyme, and filtering to obtain a single-cell suspension after digestion treatment is completed; wherein the compound digestive enzyme is prepared from collagenase, hyaluronidase and papain; and selectively, S3, carrying out red removing treatment. The invention not only provides an improved preparation method of the single-cell suspension, but also has higher efficiency on the premise of ensuring the yield and activity of single cells, and provides a new strategy and tool for cancer research and treatment by particularly enriching CSCs.

The invention provides a monoclonal antibody of a targeted human folate receptor alpha (FR1). Specifically, a mouse is immunized through FR1 recombinant protein, and a monoclonal antibody with high affinity to FR1 is screened out. In addition, the invention also provides an amino acid sequence of the monoclonal antibody, nucleic acid containing the sequence, a carrier or a conjugate containing the nucleic acid, and application of the monoclonal antibody in FR1 overexpressed tumors / cancers.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb68 or an antigen binding fragment, the anti-T3 antibody mAb68 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is TAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb68 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, a clinical sample is detected through a magnetochemiluminescence method, and the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The invention discloses a cell and a method for detecting the activity of a GLP-1R / GIPR double-target agonist drug. The invention relates to a cell for co-expressing GLP-1R, GIPR and CRE-miniP-luciferase reporter genes, and provides a method for detecting the biological activity of a GLP-1R / GIPR double-target agonist drug based on the cell, and the method is simple to operate, short in test period, sensitive in reaction, small in variability, strong in specificity and high in accuracy, can be used for release inspection of products, and can be used for detecting the biological activity of the GLP-1R / GIPR double-target agonist drug. The method has important significance on quality control and clinical application of GLP-1R / GIPR double-target agonist drugs.

The invention discloses a serum-free full-suspension MDCK (Madin-Darby Canine Kidney) cell and application thereof in preparation of influenza vaccines, and belongs to the field of virology and biological medicines. The serum-free full-suspension MDCK cell is preserved in the China Center for Type Culture Collection, is classified and named as a canine kidney cell MDCK-JHS, and has a preservation number of CCTCC NO: C2024373. The invention further provides a method for culturing the influenza virus by using the cell line, high-titer amplification of the influenza virus can be realized, and the method is suitable for industrial production.